Sacral Neuromodulation for Pelvic Pain Associated With Endometriosis
Primary Purpose
Endometriosis
Status
Unknown status
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Sacral Neuromodulation
Sponsored by
About this trial
This is an interventional treatment trial for Endometriosis focused on measuring Sacral Nerve Modulation
Eligibility Criteria
Inclusion Criteria:
- Life interfering pelvic pain with no other obvious pathology than endometriosis, that has been histologically confirmed at previous surgery.
- History of radical or fertility sparing endometriosis surgery either without obvious recurrent or residual endometriosis at gynecological examination and pelvic imaging (transvaginal ultrasound examination and/or pelvic MRI) or with recurrent or residual endometriosis, but re-operation is not desirable.
- Other treatment options, i.e. hormonal treatments and pain medications, are in use or have been tested, but they are ineffective or not possible to use due to contraindications or side effects..
Exclusion Criteria:
- Present or future desire to become pregnant
Sites / Locations
- Turku University Hospital (Tyks) Main HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Sacral neuromodulation
Arm Description
The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
Outcomes
Primary Outcome Measures
Pelvic pain intensity and frequency
Pain is evaluated with Patient's pain diary: self-reported daily pain intensity (NRS 0-10) for dysmenorrhea, non-cyclic pelvic pain, dyschezia, dysuria and dyspareunia during one month period. NRS= numerical rating scale with 0 meaning "no pain" and 10 meaning "Worst pain one can imagine"
Secondary Outcome Measures
Pelvic pain intensity
Pain is evaluated with Brief Pain Inventory Questionnaire at clinical visits
Disease specific health-related quality of life
Endometriosis Health Profile Questionnaire (EHP-30)
General health-related Quality of life
15D-measure
Sexual health-related quality of life
McCoy Female Sexuality Questionaire
Pelvic organ dysfunction symptoms
Pelvic Floor Distress Inventory (PFDI-20)
Patient satisfaction with sacral neuromodulation treatment
Evaluation of satisfaction with sacral neuromodulation treatment evaluated with NRS 0-10 (0= totally dissatisfied and 10= totally satisfied)
Full Information
NCT ID
NCT03139734
First Posted
April 7, 2017
Last Updated
May 14, 2021
Sponsor
Seinajoki Central Hospital
Collaborators
Helsinki University Central Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital, Jyväskylä Central Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03139734
Brief Title
Sacral Neuromodulation for Pelvic Pain Associated With Endometriosis
Official Title
Sacral Neuromodulation for Pelvic Pain Associated With Endometriosis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 24, 2017 (Actual)
Primary Completion Date
May 2022 (Anticipated)
Study Completion Date
May 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seinajoki Central Hospital
Collaborators
Helsinki University Central Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital, Jyväskylä Central Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to find out if sacral neuromodulation is an effective treatment for pelvic pain associated with surgically treated endometriosis.
Detailed Description
Endometriosis is typically associated with severe pelvic pain and pain is often combined with dysfunctional symptoms of the urinary bladder and the bowel. Endometriosis impairs the health-related quality of life and pain is the main reason for the decreased quality of life. When the primary endometriosis treatments, i.e. hormonal therapy and surgery, fail to alleviate pain or symptoms recur after successful treatment, the options are often limited. Recurrent or long-lasting endometriosis pain commonly involves neuropathic pain component with periferal or central sensitisation to pain. This kind of pain is likely more resistant to traditional endometriosis treatments and thus neuromodulation offers a logical treatment option.
There are some case series and at least one randomized trial describing the effect of Sacral Neuromodulation in chronic pelvic pain associated with interstitial cystitis and painful bladder syndrome. These reports indicate that Sacral Neuromodulation may be effective in treating chronic pelvic pain but the level of evidence is low. There is one report on long-term pelvic pain with Visual Analogue Scale score dropping from 8.1 to 2.1 and the effect lasting for five years. There are also few case reports on different difficult sacral area pain conditions treated successfully with Sacral Nerve Modulation. The common consensus seems to be that further studies are needed on the effects of Sacral Neuromodulation on chronic pelvic pain.
This study aims to evaluate if sacral neuromodulation alleviates pelvic pain symptoms and related dysfunctional symptoms in surgically treated endometriosis patients and improves their health-related quality of life. The treating gynecologist does the screening for suitable patients and a signed informed consent is needed from the patients prior to entering the study. A test pulse generator is placed uni- or bilaterally under local or general anesthesia and used during a 2-3-week test period. A permanent pulse generator is placed if marked improvement of symptoms is detected, the patient is satisfied with the treatment and willing to continue. Women not responding to sacral neuromodulation will not receive a permanent generator. They are asked to continue in the 3 year follow-up and they serve as the control group if applicable.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometriosis
Keywords
Sacral Nerve Modulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sacral neuromodulation
Arm Type
Other
Arm Description
The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
Intervention Type
Device
Intervention Name(s)
Sacral Neuromodulation
Other Intervention Name(s)
Sacral Nerve Stimulation, Sacral Nerve Modulation
Intervention Description
S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
Primary Outcome Measure Information:
Title
Pelvic pain intensity and frequency
Description
Pain is evaluated with Patient's pain diary: self-reported daily pain intensity (NRS 0-10) for dysmenorrhea, non-cyclic pelvic pain, dyschezia, dysuria and dyspareunia during one month period. NRS= numerical rating scale with 0 meaning "no pain" and 10 meaning "Worst pain one can imagine"
Time Frame
Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years
Secondary Outcome Measure Information:
Title
Pelvic pain intensity
Description
Pain is evaluated with Brief Pain Inventory Questionnaire at clinical visits
Time Frame
Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years
Title
Disease specific health-related quality of life
Description
Endometriosis Health Profile Questionnaire (EHP-30)
Time Frame
Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years
Title
General health-related Quality of life
Description
15D-measure
Time Frame
Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years
Title
Sexual health-related quality of life
Description
McCoy Female Sexuality Questionaire
Time Frame
Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years
Title
Pelvic organ dysfunction symptoms
Description
Pelvic Floor Distress Inventory (PFDI-20)
Time Frame
Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years
Title
Patient satisfaction with sacral neuromodulation treatment
Description
Evaluation of satisfaction with sacral neuromodulation treatment evaluated with NRS 0-10 (0= totally dissatisfied and 10= totally satisfied)
Time Frame
Change measures 1-2 months after initiation of the sacral neuromodulation and then every 6 months for 3 years
Other Pre-specified Outcome Measures:
Title
The need for sick-leave due to pelvic pain/endometriosis
Description
Number of sick-leave days/week during 6 months period
Time Frame
Change measures: retrospectively asked at baseline and then every 6 months during the 3 year follow-up
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
gender identity
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Life interfering pelvic pain with no other obvious pathology than endometriosis, that has been histologically confirmed at previous surgery.
History of radical or fertility sparing endometriosis surgery either without obvious recurrent or residual endometriosis at gynecological examination and pelvic imaging (transvaginal ultrasound examination and/or pelvic MRI) or with recurrent or residual endometriosis, but re-operation is not desirable.
Other treatment options, i.e. hormonal treatments and pain medications, are in use or have been tested, but they are ineffective or not possible to use due to contraindications or side effects..
Exclusion Criteria:
Present or future desire to become pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Adrian Zegrea
Phone
+35864153405
Email
adrian.zegrea@epshp.fi
First Name & Middle Initial & Last Name or Official Title & Degree
Tarja Pinta
Email
tarja.pinta@epshp.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Teuvo Tammela
Organizational Affiliation
Tampere University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Turku University Hospital (Tyks) Main Hospital
City
Turku
State/Province
Varsinais-Suomi
ZIP/Postal Code
20521
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emilia Ojala, MD
First Name & Middle Initial & Last Name & Degree
Emilia Ojala, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Sacral Neuromodulation for Pelvic Pain Associated With Endometriosis
We'll reach out to this number within 24 hrs